| Not Yet Recruiting | Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer NCT07243067 | Mayo Clinic | — |
| Not Yet Recruiting | GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours NCT07297667 | Canadian Cancer Trials Group | Phase 1 |
| Not Yet Recruiting | Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC) NCT06770855 | Abramson Cancer Center at Penn Medicine | N/A |
| Recruiting | Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC NCT07397611 | Dana-Farber Cancer Institute | Phase 2 |
| Withdrawn | A Novel Haemostatic Agent for Robotic Partial Nephrectomy NCT07284953 | The Royal Wolverhampton Hospitals NHS Trust | N/A |
| Recruiting | A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) NCT07195682 | Bristol-Myers Squibb | Phase 1 |
| Recruiting | Retifanlimab and Ruxolitinib In Solid Malignancies NCT07219576 | University of California, San Diego | Phase 1 / Phase 2 |
| Not Yet Recruiting | Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma NCT07346404 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Not Yet Recruiting | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors NCT07252661 | AccSalus Biosciences, Inc. | Phase 1 |
| Recruiting | Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cel NCT07300241 | Neomorph, Inc | Phase 1 |
| Recruiting | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and NCT07285044 | Mayo Clinic | Phase 2 |
| Recruiting | A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant The NCT07227402 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma NCT07123090 | Stephanie Berg | Phase 2 |
| Recruiting | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy NCT07223424 | Diwakar Davar | Phase 2 |
| Recruiting | A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda NCT07160335 | Shanghai Henlius Biotech | Phase 1 |
| Recruiting | DESTINY-PANTUMOUR04 NCT07124000 | AstraZeneca | — |
| Recruiting | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers NCT06966024 | Deciphera Pharmaceuticals, LLC | Phase 1 |
| Recruiting | IDOV-Immune for Advanced Solid Tumors NCT06910657 | ViroMissile, Inc. | Phase 1 |
| Active Not Recruiting | 177LuPSMA in Renal Cell Carcinoma NCT06964958 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043 | AstraZeneca | Phase 1 / Phase 2 |
| Recruiting | Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Diseas NCT07049926 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Withdrawn | Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases NCT07011849 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma NCT07301827 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | N/A |
| Recruiting | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With S NCT06682793 | A2 Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Suspended | Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC NCT06860386 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Recruiting | Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma NCT06376669 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Recruiting | A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma NCT06699602 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma NCT07018037 | Regina Elena Cancer Institute | — |
| Enrolling By Invitation | Drug Screening Using Novel IMD in Renal Cell Carcinoma NCT05700461 | Oliver Jonas | Phase 1 |
| Active Not Recruiting | Evaluation of a Simple-Prep Controlled Embolic NCT06453642 | Fluidx Medical Technology, Inc. | N/A |
| Terminated | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer NCT06580938 | Pfizer | Phase 1 |
| Not Yet Recruiting | Delving Into Participation Trends in Renal Cell Carcinoma Studies NCT06093568 | Power Life Sciences Inc. | — |
| Recruiting | Comparison of Postoperative Analgesic Efficacy of the Erector Spina Plane Block and Quadratus Lumborum Block i NCT05810571 | Kocaeli University | N/A |
| Recruiting | A Study of VET3-TGI in Patients With Solid Tumors NCT06444815 | KaliVir Immunotherapeutics | Phase 1 |
| Recruiting | Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable R NCT06586658 | Shanghai Changzheng Hospital | EARLY_Phase 1 |
| Terminated | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With NCT06546553 | Pfizer | Phase 1 |
| Not Yet Recruiting | A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic NCT06585878 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | N/A |
| Not Yet Recruiting | Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients NCT06577961 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 / Phase 2 |
| Recruiting | Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma NCT06318871 | Dana-Farber Cancer Institute | EARLY_Phase 1 |
| Recruiting | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma NCT06582017 | Nammi Therapeutics Inc | Phase 1 |
| Recruiting | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369 | 7 Hills Pharma, LLC | Phase 1 / Phase 2 |
| Not Yet Recruiting | Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitor NCT06523049 | Hao Zeng | Phase 2 |
| Recruiting | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours NCT06147037 | AstraZeneca | Phase 1 |
| Not Yet Recruiting | A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma NCT06472895 | Peking University Cancer Hospital & Institute | Phase 1 / Phase 2 |
| Recruiting | Planning Operative Strategy Using a Digital Renal Artery Clamping Tool NCT06536439 | University Hospital, Ghent | N/A |
| Recruiting | Oncological and Perioperative Outcomes of Laparoscopic Versus Robotic Partial Nephrectomy for Treatment of Ren NCT06424080 | Menoufia University | N/A |
| Terminated | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors NCT06299163 | Numab Therapeutics AG | Phase 1 |
| Unknown | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults NCT05949424 | University Medical Center Groningen | Phase 4 |
| Recruiting | Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected NCT06265285 | Mayo Clinic | Phase 2 |
| Recruiting | A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma NCT06234605 | HiberCell, Inc. | Phase 1 |
| Not Yet Recruiting | A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors NCT06383507 | Zhejiang University | Phase 1 |
| Active Not Recruiting | A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). NCT06307431 | Merck Sharp & Dohme LLC | Phase 2 |
| Unknown | Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis NCT06363123 | Beijing Friendship Hospital | — |
| Recruiting | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Sol NCT06265025 | GeneMedicine Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors NCT06285097 | Pfizer | Phase 1 |
| Recruiting | Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma NCT06211790 | Fudan University | Phase 2 |
| Unknown | Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant T NCT06182644 | Guangdong Provincial People's Hospital | N/A |
| Recruiting | Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma NCT06053658 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) NCT06005818 | University of Alabama at Birmingham | Phase 2 |
| Recruiting | The Cold Ischemia Robot-assisted Partial Nephrectomy NCT07326280 | Sun Yat-sen University | N/A |
| Active Not Recruiting | A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase NCT06099782 | Merck Sharp & Dohme LLC | Phase 2 |
| Recruiting | Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) NCT04974671 | Yale University | Phase 2 |
| Recruiting | Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC) NCT05931393 | University of Texas Southwestern Medical Center | Phase 2 |
| Recruiting | DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Pos NCT05770037 | Cancer Research UK | Phase 2 / Phase 3 |
| Recruiting | A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy NCT06255223 | Jinling Hospital, China | Phase 2 |
| Recruiting | Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus NCT05969496 | University of Colorado, Denver | Phase 2 |
| Recruiting | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumo NCT06010875 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogre NCT05830058 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma NCT05808608 | Hao Zeng | Phase 1 / Phase 2 |
| Unknown | Low Pressure Versus Standard Pressure Pneumoperitoneum in Laparoscopic Nephrectomy NCT06134700 | Institute of medicine, Maharagjung medical campus | N/A |
| Unknown | Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma NCT06129955 | Sun Yat-sen University | Phase 2 |
| Terminated | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Can NCT06034860 | Molecular Templates, Inc. | Phase 1 |
| Recruiting | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Meta NCT06047379 | Neonc Technologies, Inc. | Phase 1 / Phase 2 |
| Unknown | The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy NCT06342323 | Peking University Third Hospital | — |
| Recruiting | Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER) NCT06101290 | University of California, Davis | N/A |
| Not Yet Recruiting | Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Ad NCT06032728 | First Affiliated Hospital, Sun Yat-Sen University | N/A |
| Unknown | A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma NCT06049030 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy NCT05725421 | Case Comprehensive Cancer Center | N/A |
| Recruiting | Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell NCT06391879 | Peking University First Hospital | — |
| Not Yet Recruiting | Primary Metastatic Renal Cell Carcinoma Treated With Immunecheckpoint Inhibitors and Cytoreductive Nephrectomy NCT05941169 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | N/A |
| Recruiting | PET/MR for Characterization of Renal Masses (RMs) NCT06076538 | University of Texas Southwestern Medical Center | — |
| Recruiting | A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue NCT05837767 | Memorial Sloan Kettering Cancer Center | N/A |
| Unknown | CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma NCT06182735 | Fudan University | Phase 1 |
| Active Not Recruiting | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors NCT05858736 | OncoC4, Inc. | Phase 1 |
| Active Not Recruiting | Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunother NCT05703269 | Wake Forest University Health Sciences | N/A |
| Active Not Recruiting | A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma NCT05256472 | Akeso | Phase 2 |
| Terminated | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors NCT05769959 | Hoffmann-La Roche | Phase 1 |
| Completed | Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside NCT06020651 | Institut Mutualiste Montsouris | N/A |
| Active Not Recruiting | A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors NCT05867303 | RemeGen Co., Ltd. | Phase 1 |
| Completed | The Pharmacological Effects of Using Cabozantinib With a Light Breakfast NCT05263245 | dr. Tom van der Hulle | Phase 2 |
| Not Yet Recruiting | Evaluation of the Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Advanced Renal Cell NCT05798455 | Tabriz University of Medical Sciences | Phase 1 / Phase 2 |
| Withdrawn | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss NCT06090318 | Rain Oncology Inc | Phase 1 / Phase 2 |
| Completed | A Study of CDX-585 in Patients With Advanced Malignancies NCT05788484 | Celldex Therapeutics | Phase 1 |
| Active Not Recruiting | A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced So NCT05789069 | HiFiBiO Therapeutics | Phase 1 |
| Recruiting | Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma NCT05733715 | Abramson Cancer Center at Penn Medicine | EARLY_Phase 1 |
| Unknown | A Study of BPI-452080 in Subjects With Solid Tumors NCT05843305 | Betta Pharmaceuticals Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advan NCT05805501 | Hoffmann-La Roche | Phase 2 |
| Recruiting | Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma NCT05738694 | ZHOU FANGJIAN | Phase 3 |
| Recruiting | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies NCT05783622 | Janux Therapeutics | Phase 1 |
| Active Not Recruiting | Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy NCT05887245 | Centre of Postgraduate Medical Education | — |
| Recruiting | Partial Volume High-Dose Irradiation in Renal Cell Carcinoma for Intra-TUmoural Control ALongside Current Mana NCT06995664 | Royal Marsden NHS Foundation Trust | N/A |
| Terminated | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) NCT05721222 | Genmab | Phase 1 / Phase 2 |
| Terminated | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours NCT05714553 | NuCana plc | Phase 1 / Phase 2 |
| Terminated | CD8 Minibody Repeatability Study NCT05744128 | ImaginAb, Inc. | Phase 2 |
| Recruiting | Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carci NCT05188118 | Icahn School of Medicine at Mount Sinai | EARLY_Phase 1 |
| Active Not Recruiting | Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line NCT05501054 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Unknown | The Efficacy and Safety of Chinese Domestic Surgical Robot System in Urological Telesurgery NCT05739812 | The Affiliated Hospital of Qingdao University | N/A |
| Completed | Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrosp NCT05650164 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | — |
| Recruiting | National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC) NCT05326620 | PROspective Renal Cancer Cohort Foundation | — |
| Active Not Recruiting | A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combi NCT05661955 | BeiGene | Phase 1 / Phase 2 |
| Recruiting | Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus NCT05319015 | University of Texas Southwestern Medical Center | Phase 2 |
| Active Not Recruiting | A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors NCT05653882 | Asher Biotherapeutics, Inc. | Phase 1 |
| Unknown | A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immu NCT05705583 | Zhejiang Cancer Hospital | — |
| Recruiting | Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study) NCT05917106 | Jinling Hospital, China | — |
| Recruiting | A Prospective Study to Evaluate the Implementation of Shared Decision Making Strategy for Renal Cell Cancer (R NCT05548621 | St. Antonius Hospital | — |
| Recruiting | Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation NCT05641935 | john eisenbrey | Phase 2 |
| Unknown | 68Ga-labeled NY104 PET Imaging in Patients NCT05638256 | Affiliated Hospital of Jiangnan University | EARLY_Phase 1 |
| Unknown | Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes NCT05534854 | RenJi Hospital | — |
| Withdrawn | A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona NCT05418387 | University of Arizona | N/A |
| Recruiting | A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma NCT05048212 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Immunological Variables Associated to ICI Toxicity in Cancer Patients NCT05429866 | Jules Bordet Institute | Phase 2 |
| Terminated | ITIL-306 in Advanced Solid Tumors NCT05397093 | Instil Bio | Phase 1 |
| Unknown | Oncological and Functional Outcomes of Laparoscopic Partial Nephrectomy in Renal Cell Carcinoma Stages T1 Vers NCT05486871 | Sohag University | N/A |
| Withdrawn | iConquerFear Program for the Treatment of Fear of Cancer Recurrence in Patients With Localized Renal Cell Carc NCT04688333 | City of Hope Medical Center | — |
| Active Not Recruiting | A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants NCT05468697 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Unknown | A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T NCT05468190 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Completed | Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC NCT05485896 | Tianjin Medical University Second Hospital | Phase 2 |
| Recruiting | Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer NCT04981509 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors NCT05518253 | Weijia Fang, MD | Phase 1 |
| Unknown | REduced Frequency ImmuNE Checkpoint Inhibition in Cancers NCT04913025 | University College, London | Phase 2 |
| Unknown | Biomarkers of Response to Systemic Treatments in FH-deficient RCC NCT05243173 | RenJi Hospital | — |
| Unknown | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors NCT05311618 | NGM Biopharmaceuticals, Inc | Phase 1 |
| Unknown | Biomarkers of Angiogenesis for Response to Therapeutic Combination in Advanced or Metastatic Kidney Cancer NCT05285579 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of So NCT05363072 | Pfizer | — |
| Active Not Recruiting | A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 NCT05354102 | Biomica Ltd. | Phase 1 |
| Active Not Recruiting | Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer NCT05148546 | The Netherlands Cancer Institute | Phase 2 |
| Terminated | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors NCT05229601 | HiFiBiO Therapeutics | Phase 1 |
| Completed | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors NCT05293496 | MacroGenics | Phase 1 |
| Active Not Recruiting | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced o NCT05215574 | NGM Biopharmaceuticals, Inc | Phase 1 |
| Active Not Recruiting | PRO-VISION: Patient Reported Outcomes-Based Monitoring of VEGF-Inhibitor Side Effects in ONcology NCT05592665 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Active Not Recruiting | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced So NCT05238883 | HiFiBiO Therapeutics | Phase 1 |
| Recruiting | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy NCT05621837 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Recruiting | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in NCT05078047 | UNICANCER | Phase 3 |
| Completed | Circulating and Urinary Exosomal miRNA as Predictors of Treatment Response in Advanced Kidney Cancer NCT07436416 | Institute of Oncology Ljubljana | N/A |
| Active Not Recruiting | P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors NCT05239143 | Poseida Therapeutics, Inc. | Phase 1 |
| Completed | NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts NCT04960059 | The Christie NHS Foundation Trust | — |
| Terminated | Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma NCT04955743 | Yale University | Phase 2 |
| Active Not Recruiting | Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population NCT05863052 | University of Oklahoma | — |
| Unknown | A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors NCT05420545 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Unknown | Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer NCT05420519 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Active Not Recruiting | Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies NCT05013099 | ImaginAb, Inc. | Phase 2 |
| Unknown | Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma NCT05124431 | Fudan University | Phase 2 |
| Unknown | Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617 NCT05170555 | Peking Union Medical College Hospital | N/A |
| Unknown | 68Ga-NY104 PET/CT Imaging in Renal Cell Carcinoma NCT05902377 | Peking Union Medical College Hospital | Phase 2 |
| Recruiting | The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors NCT05037825 | VastBiome | — |
| Recruiting | Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors NCT05024214 | 3D Medicines (Sichuan) Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Circulating and Urinary Exosomal miRNA in Advanced Kidney Cancer (EXO-RENAL1) NCT07406646 | Institute of Oncology Ljubljana | N/A |
| Terminated | A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma NCT05119335 | NiKang Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit) NCT05056077 | University of California, San Francisco | N/A |
| Active Not Recruiting | A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or With NCT05030506 | Merck Sharp & Dohme LLC | Phase 1 |
| Not Yet Recruiting | Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT NCT05023265 | Sunnybrook Health Sciences Centre | N/A |
| Completed | Circulating Tumor Cell Reducing No-touch Nephrectomy NCT05070637 | Hospital de Santa Maria, Portugal | N/A |
| Completed | Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: NCT05012865 | Pfizer | — |
| Active Not Recruiting | Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell NCT04987203 | AVEO Pharmaceuticals, Inc. | Phase 3 |
| Recruiting | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation NCT05059444 | Guardant Health, Inc. | — |
| Terminated | Study of INCB086550 in Select Solid Tumors NCT04629339 | Incyte Corporation | Phase 2 |
| Unknown | Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Ca NCT04995016 | Tianjin Medical University Second Hospital | Phase 2 |
| Recruiting | [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma NCT04989959 | Orhan Kemal Oz | Phase 1 |
| Recruiting | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 NCT04787042 | Simcha IL-18, Inc. | Phase 1 / Phase 2 |
| Unknown | A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer NCT04958473 | Tianjin Medical University Second Hospital | Phase 2 |
| Completed | A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients NCT05375136 | Eisai Korea Inc. | — |
| Active Not Recruiting | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Mal NCT04913337 | NGM Biopharmaceuticals, Inc | Phase 1 / Phase 2 |
| Completed | A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) NCT04834778 | HiberCell, Inc. | Phase 1 |
| Unknown | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors NCT04903873 | Eutilex | Phase 1 / Phase 2 |
| Unknown | Yorkshire Kidney Screening Trial NCT05005195 | University of Leeds | N/A |
| Completed | The Registry of Oncology Outcomes Associated With Testing and Treatment NCT04028479 | Taproot Health | — |
| Recruiting | Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiothe NCT04892849 | University of Erlangen-Nürnberg Medical School | — |
| Completed | Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma NCT04804813 | Takeda | — |
| Terminated | Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic NCT04831138 | University of Texas Southwestern Medical Center | N/A |
| Unknown | The Evaluation of Functional Parenchymal Volume and Split Renal Function Before and After Partial Nephrectomy NCT04798963 | I.M. Sechenov First Moscow State Medical University | N/A |
| Completed | Research on the Effectiveness and Safety of Remote Control of Domestic Surgical Robot System for Urinary Surge NCT04804163 | The Affiliated Hospital of Qingdao University | EARLY_Phase 1 |
| Completed | To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients NCT04682587 | Pfizer | — |
| Suspended | Evaluating the Bacterial and Fungal Microbiome in Patients With Calcium Oxalate Urolithiasis and Renal Cell Ca NCT04669860 | University of Miami | — |
| Completed | Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRC NCT04704219 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Fecal Microbiota Transplantation to Improve Efficacy of Immune Checkpoint Inhibitors in Renal Cell Carcinoma NCT04758507 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 1 / Phase 2 |
| Completed | Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer NCT04883827 | Vanderbilt-Ingram Cancer Center | — |
| Unknown | VETC, Prognostic and Predictive Value in Renal Cell Carcinoma and Adrenal Carcinoma NCT04666220 | Humanitas Clinical and Research Center | — |
| Withdrawn | A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation NCT04262375 | University Health Network, Toronto | Phase 2 |
| Active Not Recruiting | A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors NCT04707248 | Daiichi Sankyo | Phase 1 |
| Completed | Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma NCT04535687 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 2 |
| Terminated | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors NCT04628780 | Pfizer | Phase 1 |
| Unknown | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity NCT04631731 | Western Sydney Local Health District | Phase 1 / Phase 2 |
| Completed | Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC) NCT04508725 | Stanford University | N/A |
| Unknown | Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief NCT04177056 | Hamilton Health Sciences Corporation | N/A |
| Unknown | Residual Normal Renal Parenchymal and Tumor Volume in Tumor Surgeries NCT04244136 | Assiut University | — |
| Completed | Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England NCT04637204 | Ipsen | — |
| Terminated | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy NCT04596033 | Genocea Biosciences, Inc. | Phase 1 |
| Withdrawn | Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (R NCT04609800 | Ipsen | — |
| Active Not Recruiting | Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC NCT04413123 | Bradley A. McGregor, MD | Phase 2 |
| Terminated | A Study of PY314 in Subjects With Advanced Solid Tumors NCT04691375 | Ikena Oncology | Phase 1 |
| Unknown | Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell C NCT04609293 | Peking University First Hospital | — |
| Completed | The Incidence of Pulmonary Embolism During Nephrectomy NCT04402749 | Mahidol University | — |
| Terminated | PET/MR Characterization of Renal Cell Carcinomas NCT04271254 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Terminated | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic NCT04260802 | Ocellaris Pharma, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Anesthesia and Cancer Study: Renal Cell Carcinoma NCT04503148 | Seoul National University Hospital | N/A |
| Withdrawn | Axitinib Therapy Management Study NCT04555603 | Pfizer | — |
| Active Not Recruiting | A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Mela NCT04495257 | Yale University | Phase 1 |
| Completed | A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor NCT04540705 | Bristol-Myers Squibb | Phase 1 |
| Terminated | A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma NCT04088500 | Bristol-Myers Squibb | Phase 2 |
| Withdrawn | PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advance NCT03598816 | Washington University School of Medicine | Phase 2 |
| Completed | Efficacy and Safety of Clinical Telesurgery Using Chinese Independently Developed Surgical Robot System NCT04570176 | The Affiliated Hospital of Qingdao University | N/A |
| Terminated | Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Pr NCT04429321 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Terminated | Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcino NCT04495894 | Emory University | Phase 2 |
| Withdrawn | MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial NCT04580836 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies NCT04440943 | Celldex Therapeutics | Phase 1 |
| Completed | Advantage of a Fast-recovery Protocol for Minimally Invasive Kidney Surgery NCT04601129 | University Hospital, Lille | — |
| Terminated | Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic NCT04267120 | Washington University School of Medicine | Phase 2 |
| Terminated | Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma NCT04341740 | University of Oklahoma | N/A |
| Unknown | Assessing the Utility of Ultrasound Compared to Cross-Sectional Imaging in the Follow-up of Patients With Rena NCT04424472 | University of Kansas Medical Center | N/A |
| Recruiting | CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition NCT04322955 | Mark Stein | Phase 2 |
| Terminated | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (CO NCT04438083 | CRISPR Therapeutics AG | Phase 1 |
| Unknown | Robotic-assisted vs. Open Partial Nephrectomy NCT04534998 | Universitätsmedizin Mannheim | Phase 2 |
| Active Not Recruiting | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab NCT04074967 | Dan Zandberg | Phase 1 / Phase 2 |
| Terminated | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors NCT04301011 | Turnstone Biologics, Corp. | Phase 1 |
| Unknown | Sintilimab in FH-deficient Renal Cell Carcinoma NCT04146831 | West China Hospital | Phase 2 |
| Completed | Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer NCT04337970 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma NCT04260360 | NanOlogy, LLC | Phase 1 |
| Recruiting | A Multicenter Cancer Biospecimen Collection Study NCT04510129 | Cofactor Genomics, Inc. | — |
| Active Not Recruiting | Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation NCT04163289 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 1 |
| Terminated | Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hyperten NCT03709771 | Vanderbilt University Medical Center | — |
| Completed | Significance of Immunohistochemical Expression of Survivin in Renal Cell Carcinoma NCT04873180 | Sohag University | — |
| Unknown | Meta-analysis of the Prognostic Value of Lymphocyte to Monocyte Ratio (LMR) in Non-metastatic Renal Cell Carci NCT04213664 | Corporacion Parc Tauli | — |
| Unknown | Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal NCT03961698 | Infinity Pharmaceuticals, Inc. | Phase 2 |
| Completed | Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology NCT03948724 | Institut Cancerologie de l'Ouest | N/A |
| Active Not Recruiting | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanc NCT04198766 | Inhibrx Biosciences, Inc | Phase 1 / Phase 2 |
| Unknown | 3D-biomodels for Surgical Planning in Patients With Renal Cancer and Vascular Involvement NCT03738488 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | N/A |
| Terminated | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. NCT04152018 | Pfizer | Phase 1 |
| Completed | Spanish Real-World Evidence Cabozantinib NCT04510688 | Spanish Oncology Genito-Urinary Group | — |
| Unknown | Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment. NCT04134182 | Kidney Cancer Research Bureau | Phase 2 |
| Active Not Recruiting | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid T NCT03983954 | NeoTX Therapeutics Ltd. | Phase 1 |
| Recruiting | 89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma NCT04006522 | James Brugarolas | Phase 2 |
| Recruiting | An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Bi NCT04623502 | University of Texas Southwestern Medical Center | N/A |
| Completed | Prospective Trial for Examining Hematuria Using Computed Tomography NCT04077359 | Oslo University Hospital | N/A |
| Completed | LPN in Patients With High-complex Renal Tumors NCT04933604 | Samsun Liv Hospital | — |
| Terminated | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumo NCT04060342 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Phase 1 |
| Active Not Recruiting | Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer NCT04022343 | Emory University | Phase 2 |
| Completed | A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell NCT05168436 | Bristol-Myers Squibb | — |
| Completed | Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy NCT04309617 | Pfizer | — |
| Active Not Recruiting | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advan NCT03937219 | Exelixis | Phase 3 |
| Active Not Recruiting | A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Canc NCT03873402 | Bristol-Myers Squibb | Phase 3 |
| Terminated | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumor NCT04234113 | SOTIO Biotech AG | Phase 1 |
| Recruiting | Biomarkers of Renal Cancer NCT05785052 | Biorek S.R.L. | — |
| Terminated | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular I NCT04106167 | Fate Therapeutics | — |
| Unknown | Patient Reported Outcome After Nephron Sparing Treatment of Small Renal Tumours NCT04040530 | Region of Southern Denmark | — |
| Recruiting | Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations NCT03786796 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Unknown | Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma NCT03987698 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Completed | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tum NCT03849469 | Xencor, Inc. | Phase 1 |
| Completed | Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal NCT03798626 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients NCT03776123 | Ipsen | — |
| Completed | Renal Cell Carcinoma Microenvironment Discovery Project NCT04005183 | University Health Network, Toronto | — |
| Completed | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) NCT03752398 | Xencor, Inc. | Phase 1 |
| Active Not Recruiting | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors NCT03872947 | Toray Industries, Inc | Phase 1 |
| Completed | ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) NCT03685448 | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Phase 2 |
| Completed | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas NCT03894618 | Shattuck Labs, Inc. | Phase 1 |
| Unknown | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor NCT03896958 | SpeciCare | — |
| Completed | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers NCT03829436 | Tempest Therapeutics | Phase 1 |
| Completed | Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) NCT03324373 | Yousef Zakharia | Phase 1 |
| Active Not Recruiting | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors NCT03845166 | Exelixis | Phase 1 |
| Completed | Laparoscopic Partial Nephrectomy for cT1 Tumors NCT04213157 | Samsun Liv Hospital | — |
| Unknown | Non-Invasive Diagnostics of Small Renal Masses NCT03667885 | Odense University Hospital | — |
| Completed | Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma NCT04416646 | Istituto Oncologico Veneto IRCCS | — |
| Completed | Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC NCT03699579 | Ipsen | — |
| Completed | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumo NCT03841110 | Fate Therapeutics | Phase 1 |
| Completed | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors NCT03758781 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Terminated | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Canc NCT03809624 | Inhibrx Biosciences, Inc | Phase 1 |
| Terminated | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent NCT03829501 | Kymab Limited | Phase 1 / Phase 2 |
| Unknown | Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors NCT03827837 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Withdrawn | A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell NCT03693573 | Hoffmann-La Roche | Phase 3 |
| Terminated | Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors NCT03637803 | 4D pharma plc | Phase 1 / Phase 2 |
| Unknown | Immune Related-adverse Events in Patients Receiving Immune Checkpoint Inhibitors NCT04268368 | Università Politecnica delle Marche | — |
| Completed | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors NCT03775850 | Evelo Biosciences, Inc. | Phase 1 |
| Terminated | A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's NCT03729245 | Nektar Therapeutics | Phase 3 |
| Completed | PD-L1 Expression in Japanese Renal Cell Carcinoma Patients NCT03748901 | Chugai Pharmaceutical | — |
| Active Not Recruiting | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Im NCT03228667 | ImmunityBio, Inc. | Phase 2 |
| Terminated | Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies NCT03387514 | University of Wisconsin, Madison | Phase 2 |
| Completed | A Bioequivalence Study of Sunitinib Malate Capsules. NCT05800106 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Terminated | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors NCT03621982 | ADC Therapeutics S.A. | Phase 1 |
| Completed | Cabozantinib Real-life Use for Advanced Renal Cell Carcinoma in France: a Retrospective Descriptive Non-interv NCT03744585 | Ipsen | — |
| Unknown | Endoscopic Robot-Assisted Simple Enucleation Versus Standard Robot-Assisted Partial Nephrectomy in the Treatme NCT03624673 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | N/A |
| Unknown | Role of Geminin and Mcm-2 in Prognosis of Renal Cell Carcinoma NCT03692533 | Assiut University | N/A |
| Active Not Recruiting | A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cel NCT03634540 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Completed | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies NCT03652077 | Incyte Corporation | Phase 1 |
| Completed | A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell C NCT03663946 | Bristol-Myers Squibb | — |
| Terminated | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC NCT03655613 | Apollomics (Australia) Pty. Ltd. | Phase 1 / Phase 2 |
| Withdrawn | Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma NCT03323710 | Military Institute od Medicine National Research Institute | Phase 2 |
| Completed | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine NCT03633110 | Genocea Biosciences, Inc. | Phase 1 / Phase 2 |
| Completed | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) NCT03207347 | University of Florida | Phase 2 |
| Active Not Recruiting | TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative NCT03630536 | Children's Hospital Medical Center, Cincinnati | — |
| Terminated | Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma NCT03552380 | Roberto Pili | Phase 2 |
| Completed | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Ma NCT03629756 | Arcus Biosciences, Inc. | Phase 1 |